You are here

  • Home
  • Archive
  • Volume 60, Issue Suppl 1
  • A real life retrospective analysis of drug expenditure reveals no significant cost difference between infliximab and adalimumab in the treatment of adult crohn's disease

Alerts

Article menu

Download PDFPDF

Posters
Service development
A real life retrospective analysis of drug expenditure reveals no significant cost difference between infliximab and adalimumab in the treatment of adult crohn's disease
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address